Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus | Zendy

Nathanial S Nolan | Zendy; Samantha E. Adamson | Zendy; Dominic N. Reeds | Zendy; Jane A. O’Halloran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus

Author(s) -

Nathanial S Nolan,

Samantha E. Adamson,

Dominic N. Reeds,

Jane A. O’Halloran

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab077

Subject(s) - medicine , antiretroviral therapy , adverse effect , diabetes mellitus , human immunodeficiency virus (hiv) , dolutegravir , diabetic ketoacidosis , integrase inhibitor , virology , intensive care medicine , viral load , endocrinology

Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is first line for treatment of people with human immunodeficiency virus (PWH). Emerging data suggest the possibility of adverse metabolic effects of these medications. We describe 3 cases in which PWH developed hyperglycemia and ketoacidosis within months of being switched to bictegravir-based ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research